{
    "clinical_study": {
        "@rank": "82333", 
        "arm_group": {
            "arm_group_label": "treatment with A3 SVF", 
            "arm_group_type": "Experimental", 
            "description": "These patients that have been treated.  The control patients that have not been treated."
        }, 
        "brief_summary": {
            "textblock": "To purpose of this study is to determine if treatment with SVF (Stromal Vascular Fraction)\n      has an effect on pain and inflammation associated with Osteoarthritis."
        }, 
        "brief_title": "Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis", 
        "condition_browse": {
            "mesh_term": "Osteoarthritis"
        }, 
        "detailed_description": {
            "textblock": "This is a prospective non-randomized, clinical study of 30 patients to determine safety and\n      treatment potential of A3(Adult Autologous Adipose) SVF for the pain and inflammation\n      associated with Osteoarthritis.\n\n      Patients will be treated for Osteoarthritis due to degeneration or chronic injury.  They\n      will be given autologous SVF extract derived by the A3 method mixed with activated platelets\n      from a PRP(platelet rich plasma) preparation as direct injections to the effected joints.\n      Outcomes will be tracked with WOMAC (Western Ontario and McMaster Universities Arthritis\n      Index), AUSCAN(Australian Hand Osteoarthritis Index) scores, and a general blood panel in\n      order to evaluate systemic effects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with indication of Osteoarthritis.  Can be from degeneration or chronic\n             injury.\n\n          -  Patients range from 15-90 years of age.\n\n          -  Female patients not pregnant or lactating.\n\n          -  Patients with a history of or current corticosteroid therapy will only be eligible if\n             use is suspended from 1 month prior to cell therapy.\n\n          -  Patients must be able to comply with treatment plan, laboratory tests and periodic\n             interviews.\n\n          -  Patients with adequate renal function, creatinine \u2264 1.5 mg/dl.\n\n          -  Patients with adequate blood coagulation activity, PT(INR) < 1.5, APTT <1.5\u00d7control.\n\n        Exclusion Criteria:\n\n          -  Diagnosis of cancer within 5 years prior to screening, except for cutaneous basal\n             cell or squamous cell cancer resolved by excision.\n\n          -  Signs and symptoms of clinically significant cardiac disease.\n\n          -  Diagnosis of a transient ischemic attack in the 6 months prior to screening,\n\n          -  Known allergy to anesthetic or any other components of study.\n\n          -  Patients infected with hepatitis B, C or HIV.\n\n          -  Patients with Body Mass Index (BMI) > 39kg/m2 .\n\n          -  Any other cardiovascular illness that in the opinion of the investigator would render\n             a patient unsuitable to participate in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947348", 
            "org_study_id": "A3-912-OA-801"
        }, 
        "intervention": {
            "arm_group_label": "treatment with A3 SVF", 
            "description": "Treatment interarticular and IV with A3 SVF", 
            "intervention_name": "treatment with A3 SVF", 
            "intervention_type": "Procedure", 
            "other_name": "A3 SVF, Cell Extracts, Adipose Derived Stem Cells"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 17, 2013", 
        "link": [
            {
                "description": "IRB", 
                "url": "http://www.cellmedicinesociety.org/"
            }, 
            {
                "description": "Info regarding outcome measures", 
                "url": "http://www.auscan.org/womac/index.htm"
            }
        ], 
        "location": {
            "contact": {
                "email": "drjhuh@gmail.com", 
                "last_name": "John Huh, MD", 
                "phone": "213-384-1717"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90020"
                }, 
                "name": "Dr John Huh"
            }, 
            "investigator": {
                "last_name": "John Huh, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis", 
        "overall_contact": {
            "last_name": "John Huh, MD", 
            "phone": "213 384 1717"
        }, 
        "overall_official": [
            {
                "affiliation": "Institute of Regenerative and Cellular Medicine", 
                "last_name": "Barbara Krutchkoff", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "ICMS", 
                "last_name": "John Huh, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Pain and Inflammation - WOMAC scores, comprehensive inflammation blood panel", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947348"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institute of Regenerative and Cellular Medicine", 
            "investigator_full_name": "barbara krutchkoff", 
            "investigator_title": "Dr John Huh, Los Angeles", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Pain and Mobility Assessment", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "source": "Institute of Regenerative and Cellular Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Regenerative and Cellular Medicine", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}